This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.
Study Type
OBSERVATIONAL
Enrollment
704
Beaumont Health System (BHS)
Royal Oak, Michigan, United States
Inpatient all-cause mortality
Time frame: During hospitalization, up to 6 months
Rates of major bleeding events
as defined by the International Society on Thrombosis and Hemostasis
Time frame: During hospitalization, up to 6 months
Rates of venous thromboses
Time frame: During hospitalization, up to 6 months
Intensive care unit/Step down unit length of stay
Time frame: During hospitalization, up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.